View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Novo Nordisk Submits Regulatory Application for Oral Semaglutide

Novo Nordisk has announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue tablet.

To be used as a treatment of adults with Type 2 diabetes, this once-daily oral formulation utilises Emisphere Technologies’ proprietary Eligen® SNAC Carrier Technology.

Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.

Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology